Is hydroxyurea leukemogenic in essential thrombocythemia?
A
A
Tefferi
D000208:Acute Disease; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects* / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D002066:Busulfan / Q000627:therapeutic use; D002869:Chromosome Aberrations; D002886:Chromosomes, Human, Pair 17 / Q000648:ultrastructure; D003937:Diagnosis, Differential; D018450:Disease Progression; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects* / Q000627:therapeutic use; D015994:Incidence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis; D007951:Leukemia, Myeloid / Q000139:chemically induced* / Q000453:epidemiology / Q000235:genetics; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000453:epidemiology; D010885:Pipobroman / Q000627:therapeutic use; D011087:Polycythemia Vera / Q000188:drug therapy; D012107:Research Design; D012189:Retrospective Studies; D012306:Risk; D013920:Thrombocythemia, Essential / Q000175:diagnosis / Q000188:drug therapy*
D018906:Antineoplastic Agents, Alkylating; D010885:Pipobroman; D002066:Busulfan; D006918:Hydroxyurea